

Recombinant Human BLyS/TNFSF13B/BAFF Protein

Catalog No. PKSH031909

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	BAFF;BLYS;CD257;DTL;TALL-1;TALL1;THANK;TNFSF20;ZTNF4
Species	Human
Expression Host	E.coli
Sequence	Ala 134-Leu 285
Accession	Q9Y275
Calculated Molecular Weight	18.0 kDa
Observed molecular weight	17 kDa
Tag	C-His
Bioactivity	Measure by its ability to induce IL-8 secretion in human PBMCs. The ED ₅₀ for this effect is < 0.5 ng/mL.

Properties

Purity	> 98 % as determined by reducing SDS-PAGE.
Endotoxin	< 0.1 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS,pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 98 % as determined by reducing SDS-PAGE.

Background

B lymphocyte stimulator (BLyS); also known as TNFSF13B; CD257 and BAFF; is single-pass type II membrane protein;

For Research Use Only

which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI); TNFRSF17 (BCMA); and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation; homeostasis; and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus; it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist; BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.